Accessibility Menu
Theriva Biologics logo

Theriva Biologics

(NYSEMKT) TOVX

Current Price$0.25
Market Cap$11.52M
Since IPO (2006)-100%
5 Year-100%
1 Year-44%
1 Month-6%

Theriva Biologics Financials at a Glance

Market Cap

$11.52M

Revenue (TTM)

$300.00K

Net Income (TTM)

-$21.46M

EPS (TTM)

-$2.53

P/E Ratio

-0.10

Dividend

$0.00

Beta (Volatility)

0.96 (Low)

Price

$0.25

Volume

1,708,387

Open

$0.27

Previous Close

$0.25

Daily Range

$0.25 - $0.27

52-Week Range

$0.16 - $0.86

Estimated Earnings Date

Aug 12, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Theriva Biologics

Industry

Biotechnology

Employees

16

CEO

Steven A. Shallcross, MBA, CPA

Headquarters

Rockville, MD 20850, US

TOVX Financials

Key Financial Metrics (TTM)

Gross Margin

92%

Operating Margin

-72%

Net Income Margin

-72%

Return on Equity

-139%

Return on Capital

-78%

Return on Assets

-56%

Earnings Yield

-10.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.52M

Shares Outstanding

45.89M

Volume

1.71M

Avg. Volume

25.01M

Financials (TTM)

Gross Profit

-$108.00K

Operating Income

-$15.02M

EBITDA

-$23.63M

Operating Cash Flow

-$16.67M

Capital Expenditure

-$35.00K

Free Cash Flow

-$16.70M

Cash & ST Invst.

$13.06M

Total Debt

$2.63M

Theriva Biologics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$300.00K

N/A

Gross Profit

$276.00K

N/A

Gross Margin

92.00%

N/A

Market Cap

$11.52M

N/A

Market Cap/Employee

$576.19K

N/A

Employees

20

N/A

Net Income

-$2.04M

+52.7%

EBITDA

-$2.02M

+53.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$14.43M

+44.1%

Total Debt

$3.69M

+29.4%

Accounts Receivable

$1.79M

+5.3%

Inventory

$0.00

N/A

Long Term Debt

$3.15M

+40.8%

Short Term Debt

$545.00K

-12.0%

Return on Assets

-56.10%

N/A

Return on Invested Capital

-77.67%

N/A

Free Cash Flow

-$2.46M

+48.4%

Operating Cash Flow

-$2.46M

+48.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BIVIBioVie Inc.
$1.76-1.68%
CMMBChemomab Therapeutics Ltd.
$1.52+1.00%
NKGNNKGen Biotech, Inc. Common Stock
$0.06+0.00%
MLECMoolec Science S.A.
$8.18+5.41%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$185.00-0.04%
MRVLMarvell Technology
$310.58+0.07%
INTCIntel
$133.99+0.11%
NOKNokia
$13.49-0.02%

Questions About TOVX

What is the current price of Theriva Biologics?

Theriva Biologics is trading at $0.25 per share.

What is the 52-week range for Theriva Biologics?

Over the past 52 weeks, Theriva Biologics has traded between $0.16 and $0.86.

How much debt does Theriva Biologics have?

As of the most recent reporting period, Theriva Biologics reported total debt of $3.69M.

How much cash does Theriva Biologics have on hand?

Theriva Biologics reported $14.43M in cash and cash equivalents in its most recent financial results.

What is Theriva Biologics’s dividend yield?

Theriva Biologics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.